Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266586 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
A Phase 2 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT05266586 is a Phase 2 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 119 participants.
The verdict
NCT05266586, a Phase 2 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.
Interventions
- DRUG Obicetrapib
- DRUG Ezetimibe 10mg
- OTHER Obicetrapib placebo
- OTHER Ezetimibe placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2022-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05266586
The ClinicalTrials.gov registry entry for NCT05266586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Obicetrapib is the first listed.
NCT05266586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05266586 about?
NCT05266586 is a clinical study titled "Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy". This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.
What is the current status of trial NCT05266586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2022-03-09. Estimated completion is 2022-09-08.
What interventions are being tested in trial NCT05266586?
The interventions under investigation include: Obicetrapib (DRUG), Ezetimibe 10mg (DRUG), Obicetrapib placebo (OTHER), Ezetimibe placebo (OTHER).
Who is sponsoring clinical trial NCT05266586?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.